Endocyte to cut workforce 40%

12:35 EDT 5 Jun 2017 | CentreWatch

Endocyte, a provider developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, announced updates on clinical development for EC1456, its folate receptor-targeted tubulysin cancer therapy, and EC1169, its prostate-specific membrane antigen targeted (PSMA-targeted) tubulysin prostate cancer therapy. Endocyte will narrow the EC1169 development program to focus only on the cohort […]

The post Endocyte to cut workforce 40% appeared first on CenterWatch News Online.

Original Article: Endocyte to cut workforce 40%


More From BioPortfolio on "Endocyte to cut workforce 40%"

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...